Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)

Journal of Diabetes Investigation

Volumn 7, Issue 3, 2016, Pages 386-395

  Kanatsuka, Azuma ^a   Sato, Yasunori ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Kobayashi, Masashi ^d   Kashiwagi, Atsunori ^e   Abe, Nobuyuki ^a   Arai, Keiko ^a   Fujiya, Hiroshi ^a   Fukumoto, Yoshihide ^a   Dake, Fumihiko ^a   Iizumi, Tomohiro ^a   Ito, Masaaki ^a   Iwasaki, Koichi ^a   Kanamori, Akira ^a   Kato, Sumio ^a   Kato, Masakazu ^a   Kawara, Akira ^a   Kimura, Kenichi ^a   Chikamori, Kazumasa ^a   Iemitsu, Kotaro ^a   Kou, Shigetake ^a   Kudo, Mikihiko ^a   Kurihara, Yoshio ^a   Lee, Gendai ^a   Tsuruoka, Akira ^a   Manda, Naoki ^a   Matoba, Kiyokazu ^a   Hayashi, Hiroshi ^a   Minami, Masae ^a   Kuribayashi, Nobuichi ^a   Miyazawa, Kazuhiro ^a   Chiba, Yasuko ^a   Osonoi, Takeshi ^a   Nakamura, Shin ^a   Sasaki, Hideo ^a   Komori, Katsutoshi ^a   Oishi, Mariko ^a   Okada, Akira ^a   Okuguchi, Fuminobu ^a   Yanagisawa, Morifumi ^a   Sugimoto, Hidekatsu ^a   Sugiyama, Hiromichi ^a   Takai, Masahiko ^a   Takaki, Masato ^a   Takamura, Hiroshi ^a   Takeda, Hiroshi ^a   Tanaka, Kokichi ^a   Miwa, Takashi ^a   Tomonaga, Osamu ^a   Taguchi, Madoka ^a   Yamazaki, Katsuya ^a   Wada, Takako ^a   Yagi, Noriharu ^a   Yamaoka, Kuniko ^a   Yuhara, Atsuyoshi ^a   more..

^a CHIBA UNIVERSITY   (Japan)

^b Kawai Clinic   (Japan)

^c HEC Science Clinic   (Japan)

^d Department of Neurosurgery   (Japan)

^e Kusatsu General Hospital   (Japan)

Author keywords

Oral antidiabetic drug; Propensity score matched cohort study; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; ONSET AGE; PRIORITY JOURNAL; AGED; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROPENSITY SCORE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROPENSITY SCORE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84948168962     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12430     Document Type: Article

References (37)

1. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
2. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
3. Sherifali D, Nerenberg CK, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels. Diabetes Care 2010; 33: 1859-1864.
4. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
5. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: 1-15.
6. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-2425.
7. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins, 1996
8. Concato J, Shah N, Holwitz RI. Randomized, controlled trials, observational studies, and the hierarch designs. N Engl J Med 2000; 342: 1887-1892.
9. MacKee M, Britton A, Black N, et al. Interpreting the evidence: choosing between randomized and non-randomized studies. BMJ 1999; 319: 312-315.
10. Austin CP. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
11. Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Groups International Conference, Long Beach, Calif., April 22-25, 2001, Cary, N.C.: SAS Institute, 2001
12. Sato D, Sato Y, Masuda S, et al. Effects of a sitagliptin safety on prescription behavior for oral antihyperglycemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan. Drug Saf 2013; 36: 605-615.
13. Kanatsuka1 A, Sato Y, Kawai K, et al. Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: a propensity score-matched cohort study across Japan (JDDM31). J Diabetes Investig 2014; 5: 539-549.
14. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 2006; 29: 1963-1972.
15. Kanatsuka A, Kawai K, Hirao K, et al. The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: an observational study in multiple institutes across Japan (JDDM 27). Diabetol Int 2012; 3: 164-173.
16. Kobayashi M, Yamazaki K, Hirao K et al. The status of diabetes control and antidiabetic drug therapy in Japan-A cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73: 198-204.
17. ®-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diabetes Res Clin Pract 2006; 72: 277-283.
18. Yokoyama H, Kawai K, Oishi MJ, et al. . Familial predisposition to cardiovascular risk and disease contributes to cardiovascular risk and disease interacting with other cardiovascular risk factors in diabetes-Implication for common soil. Atherosclerosis 2008; 201: 332-338.
19. Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the committee of Japan diabetes society on the classification and diagnosis of diabetes mellitus. J Japan Diab Soc 1999; 42: 395-404 (Japanese).
20. Guideline Committee of the Japan Diabetes Society. Japan diabetes society guideline for the management of diabetes based on scientific evidences. Nankodo Tokyo: Japan Diabetes Society; 2010 (Japanese).
21. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare. June 30, 2003 (Japanese).
22. Tominaga M, Makino E, Yoshino G, et al. Report of the committee on standardization of laboratory testing related to diabetes mellitus: the seventh national survey on Hemoglobin A1c. J Japan Diab Soc 2003; 46: 961-965 (Japanese).
23. American Diabetes Association. Clinical practice recomm-endations 1995. Diabetes Care 1995; 18(suppl 1): S1-S596.
24. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11: 534-544.
25. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012; 3: 39-40.
26. Treatment Guide for Diabetes Editorial Committee, the Japan Diabetes Society. The Treatment Guide for Diabetes 2007. Bunkodo Tokyo 2007
27. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88.
28. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143-156.
29. Cignarelli A, Giorgino F, Vettor R. Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. Arch Physiol Biochem 2013; 119: 139-150.
30. Inzucchi S. Oral anti-hyperglycemic therapy for type2 diabetes: scientific review. JAMA 2002; 287: 360-372.
31. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007; 24: 955-961.
32. Morsink LM, Smits MM, Diamant M. Advances in pharmacologic therapies for type2 diabetes. Curr Atheroscler Rep 2013; 15: 302.
33. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
34. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247-2256.
35. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
36. Hirssch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
37. Inzucchi S, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: a Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.